Clinical Trials Logo

Drug-eluting Stents clinical trials

View clinical trials related to Drug-eluting Stents.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04949516 Completed - Clinical trials for Acute Coronary Syndrome

Mono Antiplatelet and Colchicine Therapy

MACT
Start date: June 15, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.

NCT ID: NCT03197298 Completed - Clinical trials for Acute Coronary Syndrome

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

CHANGE DAPT
Start date: December 21, 2012
Phase: N/A
Study type: Observational [Patient Registry]

Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin). This change is based on studies that showed benefits of ticagrelor. However, study participants were only partly treated by percutaneous coronary intervention (PCI). In patients who were treated by PCI, this was generally performed using of bare metal or first-generation drug-eluting stents (DES). CHANGE DAPT is an investigator-initiated, prospective, single centre registry, in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen (from clopidogrel to ticagrelor) on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente.

NCT ID: NCT03180931 Completed - Clinical trials for Tomography, Optical Coherence

Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis

INVEST
Start date: December 2, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Bioresorbable vascular scaffold (BVS, ABSORB BVS1.1, Abbott Vascular) has been approved (CE mark) and is used in daily clinical practice. While recent randomized controlled trials comparing BVS versus metallic drug-eluting stent showed higher risk of definite or probable device thrombosis after BVS implantation, the causes underlying thrombotic events occurring beyond one year after scaffold implantation remain unclear and require investigation in an independent manner. The INVEST registry is a world-wide, multi-center, observational, retrospective, investigator-initiated registry, which will include any patients who suffered from very late (>1 year) scaffold thrombosis, underwent optical coherence tomography (OCT) at the time of thrombosis and provided informed consent for the further use of their health related data for this registry.